Gene expression profiling predicts clinical outcome of prostate cancer
J. Clin. Invest. Gennadi V. Glinsky, et al. 113:913 doi:10.1172/JCI20032 [
Go to this article.]
Figure 4Kaplan-Meier analysis of the probability that patients would remain disease-free among prostate cancer patients with Gleason sum 6 and 7 tumors (A) and patients with Gleason sum 8 and 9 tumors (B) according to whether they had good-prognosis or poor-prognosis signatures defined by the recurrence predictor algorithm or whether they had Gleason sum 8 and 9 or Gleason sum 6 and 7 prostate tumors (C).
